Pharma News

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced that the European Medicines Agency (EMA) granted Orphan Drug Designation for ADXS-HER2 for the treatment of osteosarcoma.

Biotronik, the world’s leading manufacturer of MR conditional cardiac devices, has announced that its Eluna 8 pacemaker is now available in Japan. The pacemaker is approved for 1.5 tesla (T) full-body MRI scans, and ultra-high strength 3.0 T MRI scans with an exclusion zone.

AbbVie, a global biopharmaceutical company, announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) for a once-daily, fixed-dose formulation of the components of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). VIEKIRA PAK is an all-oral, interferon-free treatment approved with or without ribavirin (RBV) in the United States for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is not for people with decompensated cirrhosis.

Chinese doctors have cured a patient of leukemia using gene therapy, a hospital in Chongqing announce. Zhang Fang, a middle-aged woman, has been cured of leukemia after she was treated with CAR T therapy, Xinhua reported.

[adsense:336x280:8701650588]

If you are planning a baby, do not just sermon your wife to eat well but control your diet first. According to a fascinating study, sperm carries key information about what new dads gulped down before the conception.

Researchers have identified a biomarker that detects the most common lung cancer in its earliest stage.

In order to bring interventions from various backgrounds under a single umbrella, a group of top neurosurgeons has come together to form India's first dedicated society for therapeutic neurointerventions.

Scientists at the Centre for DNA Fingerprinting and Diagnostics (CDFD) have discovered a novel protein which could lead to development of a therapy for tuberculosis.

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative medicines for pancreatic ductal adenocarcinoma (PDAC). The new collaboration combines MD Anderson’s unique understanding of potential drivers of PDAC with Boehringer Ingelheim’s experience in drug discovery and development.